Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI

(SAN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations
The feature you requested does not exist. However, we suggest the following feature:

Novartis : halts distribution of its Zantac versions amid probe into impurities

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/18/2019 | 11:52am EDT
FILE PHOTO: Logo of Swiss drugmaker Novartis is seen at its branch in Schweizerhalle near Basel

(Reuters) - Novartis Sandoz unit said on Wednesday it was halting distribution of its versions of the drug commonly known as Zantac in all its markets, including the United States and Canada, after contaminants were found in the heartburn drug.

The Swiss drugmaker's steps follow an investigation by U.S. and European regulators into the presence of the impurity, N-nitrosodimethylamine (NDMA), in the drug, ranitidine, and a distribution halt in Canada announced late Tuesday.

Health Canada said it had requested makers of the drug to stop distribution as it gathers more information and consults with international health regulators.

Branded versions of the drug such as Sanofi Zantac are available for over-the-counter sale in Canada, while generic versions are available for sale both OTC and with prescription.

A distribution halt is different from a recall and means that existing stock of the drugs in pharmacies or stores can still be sold.

Neither the U.S. Food and Drug Administration nor the European Medicines Agency had asked patients to stop taking the drug when the regulators said last week they were reviewing the safety of ranitidine.

Novartis said in an emailed statement its step was precautionary and adequate measures "will be implemented in alignment with relevant health authorities as required."

(Reporting by Manas Mishra in Bengaluru and Michael Erman in New York; Editing by Maju Samuel)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
09/18NOVARTIS : halts distribution of its Zantac versions amid probe into impurities
RE
09/17ABBOTT LABORATORIES : And sanofi partner to integrate glucose sensing and insuli..
AQ
09/16SANOFI : Press releases
PU
09/16SANOFI : Abbott to Collaborate on Glucose Sensing, Insulin Delivery Data
DJ
09/16Sanofi and Abbott partner to integrate glucose sensing and insulin delivery t..
GL
09/16SANOFI : and Abbott partner to integrate glucose sensing and insulin delivery te..
GL
09/13HAGENS BERMAN : National Class-Action Lawsuit Accuses Sanofi of Concealing Zanta..
BU
09/13SANOFI : FDA Finds Probable Carcinogen in Some Versions of Zantac --Update
DJ
09/13SANOFI : FDA Finds Probable Carcinogen in Some Versions of Zantac --Update
DJ
09/13SANOFI : FDA Finds Probable Carcinogen in Some Versions of Zantac
DJ
More news
Financials (EUR)
Sales 2019 36 376 M
EBIT 2019 9 484 M
Net income 2019 4 278 M
Debt 2019 14 724 M
Yield 2019 3,93%
P/E ratio 2019 24,9x
P/E ratio 2020 17,0x
EV / Sales2019 3,17x
EV / Sales2020 2,98x
Capitalization 100 B
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 87,21  €
Last Close Price 80,22  €
Spread / Highest target 24,7%
Spread / Average Target 8,72%
Spread / Lowest Target -40,2%
EPS Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Ameet Nathwani Executive Vice President-Medical Affairs
John C. Reed Head-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI6.03%111 125
JOHNSON & JOHNSON1.05%344 174
ROCHE HOLDING LTD.14.65%241 967
MERCK AND COMPANY8.65%212 562
PFIZER-16.66%201 220
NOVARTIS15.63%197 665